Nevro (NVRO) Reports Prelim Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain as chip stocks extend recovery; earnings in focus
- Oil prices rise nearly 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- Danaher shares tumble despite earnings beat
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
January 9, 2024 8:30 AM ESTFourth-Quarter 2023 Worldwide Revenue Exceeds Company's Expectations
Announces Restructuring to Support Company's Long-Term Growth and Profitability
REDWOOD CITY, Calif., Jan. 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth-quarter and full-year 2023 revenue results. The... More
